India Pesticides Limited shareholders approved all six resolutions placed before the company’s 41st annual general meeting held on August 31, 2026. The vote included the adoption of audited financial statements for FY26 and a final dividend declaration.

The meeting was conducted through video conferencing and other audio-visual means, with no physical presence of members at the venue. GSK & Associates served as the scrutinizer for the voting process.

Voting Results Overview

Shareholders holding 11,51,63,508 equity shares were eligible to vote. A total of 8,71,07,667 votes were polled, representing approximately 75.64% of outstanding shares. The promoter group held 7,33,00,698 shares, while public non-institutional investors held 4,16,87,541 shares.

Key Resolutions Passed

Financial Statements and Dividend

Shareholders adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. The board also secured approval to declare a final dividend on equity shares for FY26.

Director Re-appointments and Remuneration

The meeting approved the re-appointment of Dr. Kuruba Adeppa as Whole-Time Director, who retires by rotation under Section 152(6) of the Companies Act, 2013. Additionally, shareholders passed special resolutions to increase the remuneration of both Dr. Kuruba Adeppa and Dr. Udaya Bhaskar Mantripragada.

What the Numbers Show

The voting pattern reveals significant divergence between promoter and public shareholder sentiment regarding management compensation. While the promoter group cast zero votes against any resolution, public non-institutional investors voted against the remuneration increases for both directors with 6,887 votes each. This accounts for nearly all opposition across the special resolutions, indicating specific scrutiny from retail and non-institutional stakeholders on executive pay packages despite overwhelming overall support.

India Pesticides Limited reported a 9.2% year-on-year decline in consolidated revenue to ₹256 crore for the quarter ended June 30, 2026, compared to ₹282 crore in the corresponding period of FY26. The company’s profit after tax (PAT) fell to ₹23 crore from ₹35 crore last year, reflecting margin pressure from lower sales volumes and increased expenses.

Financial Performance

Revenue contraction was driven by a 13% decline in sales volume, partially offset by a 4% price increase. Domestic revenue dropped significantly to ₹167 crore from ₹195 crore in Q1FY26, attributed to deficient rainfall leading to delayed or non-sowing of crops, particularly affecting demand for the company’s key herbicide, Pretilachlor. Export revenue remained resilient at ₹89 crore, up slightly from ₹87 crore in the prior year quarter, contributing approximately 35% of total revenue.

EBITDA stood at ₹39 crore with a margin of 15.4%, down from ₹52 crore and 18.4% in Q1FY26. Management cited higher employee costs, increased fuel expenses, and one-time write-offs as primary drivers for the margin compression.

What the Numbers Show

The divergence between stable export performance and sharp domestic decline highlights India Pesticides’ continued dependency on monsoon-dependent agricultural cycles. While exports grew modestly, they were insufficient to offset the ₹28 crore drop in domestic revenue. Furthermore, operating expenses rose due to a one-time write-off of ₹2.5 crore on export receivables and an additional ₹6 crore in job work charges incurred in anticipation of higher seasonal demand that did not materialize in Q1.

Operational Updates & Outlook

The company received Technical Equivalence approval from the European Union for a fungicide product, potentially unlocking an additional ₹30–40 crore in annual revenue from new customers in the region. Sales for this product are expected to commence from November 2026.

India Pesticides is expanding its manufacturing capabilities through its Hamirpur facility, where two blocks are currently operational. Management expects the Hamirpur plant to contribute ₹50–60 crore in revenue this fiscal year, with long-term potential reaching ₹1,000 crore over three to four years as eight to ten production blocks are commissioned. The company plans to maintain annual capex of ₹100 crore across its Sandila and Hamirpur facilities, funded entirely through internal accruals without taking term loans.

Working capital metrics showed inventory days rising from 170 to approximately 200 days due to lower sales realization against anticipated production levels. Receivable days remained stable at around 120 days. The company maintained a healthy cash balance of ₹59 crore as of June 30, 2026.

Looking ahead, management guided for lower single-digit revenue growth for FY27, expecting improvement in Q3 and Q4 as monsoon conditions normalize. Sustainable EBITDA margins are targeted at 15–16% in the near term, with a long-term goal of returning to 18% as operational efficiencies improve and geopolitical factors stabilize.